144 related articles for article (PubMed ID: 28587939)
1. Temozolomide and sorafenib as programmed cell death inducers of human glioma cells.
Jakubowicz-Gil J; Bądziul D; Langner E; Wertel I; Zając A; Rzeski W
Pharmacol Rep; 2017 Aug; 69(4):779-787. PubMed ID: 28587939
[TBL] [Abstract][Full Text] [Related]
2. Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas.
Jakubowicz-Gil J; Langner E; Bądziul D; Wertel I; Rzeski W
Neurotox Res; 2014 Jul; 26(1):64-77. PubMed ID: 24366851
[TBL] [Abstract][Full Text] [Related]
3. Silencing of Hsp27 and Hsp72 in glioma cells as a tool for programmed cell death induction upon temozolomide and quercetin treatment.
Jakubowicz-Gil J; Langner E; Bądziul D; Wertel I; Rzeski W
Toxicol Appl Pharmacol; 2013 Dec; 273(3):580-9. PubMed ID: 24126416
[TBL] [Abstract][Full Text] [Related]
4. Involvement of PI3K Pathway in Glioma Cell Resistance to Temozolomide Treatment.
Zając A; Sumorek-Wiadro J; Langner E; Wertel I; Maciejczyk A; Pawlikowska-Pawlęga B; Pawelec J; Wasiak M; Hułas-Stasiak M; Bądziul D; Rzeski W; Reichert M; Jakubowicz-Gil J
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068110
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide, quercetin and cell death in the MOGGCCM astrocytoma cell line.
Jakubowicz-Gil J; Langner E; Wertel I; Piersiak T; Rzeski W
Chem Biol Interact; 2010 Oct; 188(1):190-203. PubMed ID: 20654599
[TBL] [Abstract][Full Text] [Related]
6. Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis.
Sehm T; Rauh M; Wiendieck K; Buchfelder M; Eyüpoglu IY; Savaskan NE
Oncotarget; 2016 Nov; 7(46):74630-74647. PubMed ID: 27612422
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis induction in human glioblastoma multiforme T98G cells upon temozolomide and quercetin treatment.
Jakubowicz-Gil J; Langner E; Bądziul D; Wertel I; Rzeski W
Tumour Biol; 2013 Aug; 34(4):2367-78. PubMed ID: 23580181
[TBL] [Abstract][Full Text] [Related]
8. Coumarins modulate the anti-glioma properties of temozolomide.
Sumorek-Wiadro J; Zając A; Bądziul D; Langner E; Skalicka-Woźniak K; Maciejczyk A; Wertel I; Rzeski W; Jakubowicz-Gil J
Eur J Pharmacol; 2020 Aug; 881():173207. PubMed ID: 32446712
[TBL] [Abstract][Full Text] [Related]
9. LY294002 and sorafenib as inhibitors of intracellular survival pathways in the elimination of human glioma cells by programmed cell death.
A Z; J SW; A M; E L; I W; W R; J JG
Cell Tissue Res; 2021 Oct; 386(1):17-28. PubMed ID: 34236519
[TBL] [Abstract][Full Text] [Related]
10. Kinetic studies of the effects of Temodal and quercetin on astrocytoma cells.
Jakubowicz-Gil J; Langner E; Rzeski W
Pharmacol Rep; 2011; 63(2):403-16. PubMed ID: 21602595
[TBL] [Abstract][Full Text] [Related]
11. Antiglioma Potential of Coumarins Combined with Sorafenib.
Sumorek-Wiadro J; Zając A; Langner E; Skalicka-Woźniak K; Maciejczyk A; Rzeski W; Jakubowicz-Gil J
Molecules; 2020 Nov; 25(21):. PubMed ID: 33171577
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib-induced defective autophagy promotes cell death by necroptosis.
Kharaziha P; Chioureas D; Baltatzis G; Fonseca P; Rodriguez P; Gogvadze V; Lennartsson L; Björklund AC; Zhivotovsky B; Grandér D; Egevad L; Nilsson S; Panaretakis T
Oncotarget; 2015 Nov; 6(35):37066-82. PubMed ID: 26416459
[TBL] [Abstract][Full Text] [Related]
13. The effect of quercetin and imperatorin on programmed cell death induction in T98G cells in vitro.
Bądziul D; Jakubowicz-Gil J; Langner E; Rzeski W; Głowniak K; Gawron A
Pharmacol Rep; 2014 Apr; 66(2):292-300. PubMed ID: 24911084
[TBL] [Abstract][Full Text] [Related]
14. Furanocoumarins as Enhancers of Antitumor Potential of Sorafenib and LY294002 toward Human Glioma Cells In Vitro.
Sumorek-Wiadro J; Zając A; Skalicka-Woźniak K; Rzeski W; Jakubowicz-Gil J
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255833
[TBL] [Abstract][Full Text] [Related]
15. Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy.
Golden EB; Cho HY; Jahanian A; Hofman FM; Louie SG; Schönthal AH; Chen TC
Neurosurg Focus; 2014 Dec; 37(6):E12. PubMed ID: 25434381
[TBL] [Abstract][Full Text] [Related]
16. NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.
Kießling MK; Nicolay JP; Schlör T; Klemke CD; Süss D; Krammer PH; Gülow K
Oncotarget; 2017 Jul; 8(28):45687-45697. PubMed ID: 28537899
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Autophagy by Chloroquine Enhances the Antitumor Efficacy of Sorafenib in Glioblastoma.
Liu X; Sun K; Wang H; Dai Y
Cell Mol Neurobiol; 2016 Oct; 36(7):1197-208. PubMed ID: 26971793
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cFLIP overcomes acquired resistance to sorafenib via reducing ER stress‑related autophagy in hepatocellular carcinoma.
Liu D; Fan Y; Li J; Cheng B; Lin W; Li X; Du J; Ling C
Oncol Rep; 2018 Oct; 40(4):2206-2214. PubMed ID: 30066934
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effect of fisetin combined with sorafenib in human cervical cancer HeLa cells through activation of death receptor-5 mediated caspase-8/caspase-3 and the mitochondria-dependent apoptotic pathway.
Lin MT; Lin CL; Lin TY; Cheng CW; Yang SF; Lin CL; Wu CC; Hsieh YH; Tsai JP
Tumour Biol; 2016 May; 37(5):6987-96. PubMed ID: 26662956
[TBL] [Abstract][Full Text] [Related]
20. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
